Download Brochure

Please complete the information below to complete your download.

Please note: That all fields marked with an asterisk (*) are required.

First Name *
Last Name *
Job Title *
Company Name *
Email Address *
Telephone *
Country *
Where did you hear about us? *

I would like to receive information about sponsorship and exhibition opportunities

Yes, sign me up for the FREE Pharma IQ e-newsletter, including information on FREE Podcasts, Webinars, event discounts and online learning opportunities.

U.S. Judicial Decisions Impacting Co-Crystal Patent Strategy

Posted: 08/25/2010

Leave this field empty
To continue viewing this content please fill out the form below and become an IQ member.
Already an IQ member? Sign in

First Name:  *
Last Name:  *
Job Title:  *
Phone:  *
E-mail:  *
Company:  *
Country:  *
User Name:  *
Password:  *
Confirm Password:  *
Which of the following best describes your area of expertise?

Tags:  Jeffrey Lindeman | patent strategies | co-crystal patents | co-crystals | crystalline forms | IP strategies | IP strategies for crystalline forms | co-crystal patentability | pharmaceutical co-crystals | patent considerations | enantiomers | salt forms

Want to design and implement effective patent strategies for co-crystal patents? In this presentation, decisions suggesting how US courts may view co-crystal patents, including analysis of Abbott v. Sandoz (Fed. Cir. 2009),  Sanofi-Synthelabo v. Apotex (Fed. Cir . 2008), and Pfizer v. Apotex (Fed. Cir. 2007). 

Presented Dr. Jeffrey A. Lindeman, Member, O’Brien Jones PLLC, at IQPC's Pharmaceutical Co-Crystals 2009.

comments powered by Disqus

Advertise With Us

Join the Pharmas IQ Community